注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
NeuroSense Therapeutics Ltd是一家以色列的临床阶段制药公司。该公司活跃于肌萎缩性侧束硬化症(ALS)患者以及其他神经退行性疾病的药物开发和治疗领域。该公司的主要候选产品PrimeC是一种由特定药物比例组成的固定剂量组合的口服制剂。除PrimeC外,该公司还启动了阿尔茨海默病和帕金森病的研发工作。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jeremy M. Shefner | - | - | Chair of Scientific Advisory Board |
Jinsy Andrews | - | - | Scientific Advisory Board Member |
Orla Hardiman | - | - | Scientific Advisory Board Member |
Jeffery Rosenfeld | - | - | Scientific Advisory Board Member |
Merit Cudkowicz | 58 | - | Scientific Advisory Board Member |
Cary John Claiborne | 62 | 2021 | Independent External Director |
Mark Wayne Leuchtenberger | 55 | 2021 | Independent Chairman of the Board |
Caren Deardorf | 57 | 2021 | Independent Director |
Revital Mandil-Levin | 49 | 2022 | Director |
Christine A. Pellizzari | 55 | 2021 | Independent External Director |
Alon Ben-Noon | 45 | 2016 | Co-Founder, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核